Deerfield Management’s ACELYRIN SLRN Stock Holding History

Deerfield Management’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-650,000	Closed	-$13.6M	–	104
2023 Q2	$13.6M	Buy	+650,000	New	+$13.3M	0.29%	61

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Deerfield Management's SLRN Position: Q3 2023 in Review

Deerfield Management sold out of ACELYRIN (SLRN) in Q3 2023, closing a stake of 650,000 shares — an estimated $13.6M sold.

Deerfield Management first reported a position in SLRN in Q2 2023 and held it in 1 quarter. The position peaked at $13.6M in Q2 2023. 101 funds tracked by Wall St. Rank hold SLRN as of Q3 2023.

Deerfield Management reported no remaining ACELYRIN position as of Q3 2023 after selling out during the quarter.
Deerfield Management sold 650,000 ACELYRIN shares in Q3 2023, an estimated $13.6M.
Deerfield Management first reported a position in ACELYRIN in Q2 2023 and held it in 1 quarter.
Deerfield Management's ACELYRIN position peaked at $13.6M in Q2 2023.
101 funds tracked by Wall St. Rank held ACELYRIN as of Q3 2023.

Based on Deerfield Management's 13F filing for Q3 2023, filed 14 Nov 2023.